CPIX

Peers: LLY JNJ NVS GILD ACAD BMRN AMRX EXEL ENTA INVA

| Held by: VTI VXF DFAS DFMC DFAT IWC AVSC DFAC DFSU

Index	-	P/E	-	EPS (ttm)	-0.19	Insider Own	42.21%	Shs Outstand	14.96M	Perf Week	-2.21%
Market Cap	46.37M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	8.64M	Perf Month	0.65%
Enterprise Value	44.77M	PEG	-	EPS next Q	-	Inst Own	19.77%	Short Float	1.65%	Perf Quarter	-35.82%
Income	-2.84M	P/S	1.04	EPS this Y	-	Inst Trans	-8.45%	Short Ratio	1.02	Perf Half Y	-15.62%
Sales	44.52M	P/B	1.86	EPS next Y	-	ROA	-3.72%	Short Interest	0.14M	Perf YTD	-22.11%
Book/sh	1.66	P/C	4.05	EPS next 5Y	-	ROE	-11.88%	52W High	6.26 -50.52%	Perf Year	-23.08%
Cash/sh	0.76	P/FCF	9.60	EPS past 3/5Y	20.68% 2.82%	ROIC	-8.20%	52W Low	1.85 67.57%	Perf 3Y	64.02%
Dividend Est.	-	EV/EBITDA	17.09	Sales past 3/5Y	1.95% 3.52%	Gross Margin	75.71%	Volatility	4.79% 7.30%	Perf 5Y	-2.21%
Dividend TTM	-	EV/Sales	1.01	EPS Y/Y TTM	58.90%	Oper. Margin	-5.98%	ATR (14)	0.21	Perf 10Y	-30.02%
Dividend Ex-Date	-	Quick Ratio	0.84	Sales Y/Y TTM	17.57%	Profit Margin	-6.37%	RSI (14)	44.08	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.01	EPS Q/Q	30.74%	SMA20	0.62%	Beta	-0.30	Target Price	9.75
Payout	-	Debt/Eq	0.41	Sales Q/Q	31.08%	SMA50	-12.48%	Rel Volume	0.47	Prev Close	3.11
Employees	93	LT Debt/Eq	0.39	Earnings	Mar 03 AMC	SMA200	-7.51%	Avg Volume	139.42K	Price	3.10
IPO	Aug 11, 2009	Option/Short	Yes / Yes	EPS/Sales Surpr.	- -	Trades		Volume	5,031	Change	-0.32%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-12-12	Reiterated	UBS	Neutral	$6.50 → $5
Feb-01-11	Reiterated	UBS	Neutral	$8 → $6.50
Dec-16-10	Downgrade	UBS	Buy → Neutral	$10 → $8
Aug-17-10	Reiterated	UBS	Buy	$11 → $10
Aug-17-10	Reiterated	Morgan Joseph	Buy	$15 → $10
Aug-17-10	Downgrade	Jefferies	Buy → Hold	$13 → $5.50
May-14-10	Reiterated	Morgan Joseph	Buy	$21 → $15

Mar-17-26 09:05AM	Cumberland Pharmaceuticals Launches New Sancuso Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting (PR Newswire)
Mar-10-26 01:49PM	Cumberland Q4 Loss Narrows Y/Y as Talicia Launch Boosts Sales (Zacks) -7.33%
Mar-04-26 12:01AM	Cumberland Pharmaceuticals Inc (CPIX) Q4 2025 Earnings Call Highlights: Revenue Surge and ... (GuruFocus.com) -19.87%
Mar-03-26 06:02PM	Cumberland Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat) -5.37%
05:15PM	Cumberland: Q4 Earnings Snapshot (Associated Press Finance)
05:00PM	Loading…
05:00PM	CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH (PR Newswire)
Feb-25-26 07:00AM	Joint U.S. Commercialization of RedHill's Talicia Commences (PR Newswire)
07:00AM	CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA (PR Newswire)
Feb-04-26 09:05AM	Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program (PR Newswire)
Jan-15-26 11:24AM	Niche Focus & Regulation Shape the Future of Healthcare Firms (Zacks)
Dec-23-25 04:00AM	Leading the charge the companies at the cutting edge of cell-based protein (Just Food)
Dec-19-25 05:02PM	Top Research Reports for NVIDIA, Netflix & Merck (Zacks)
08:53AM	Zacks Initiates Coverage of CPIX With Outperform Recommendation (Zacks)
Dec-08-25 09:05AM	CALDOLOR (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT (PR Newswire) -9.21%
Nov-05-25 12:02AM	Cumberland Pharmaceuticals Inc (CPIX) Q3 2025 Earnings Call Highlights: Strategic Product ... (GuruFocus.com) -12.41%
05:33PM	Loading…
Nov-04-25 05:33PM	Cumberland: Q3 Earnings Snapshot (Associated Press Finance)
05:00PM	CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH (PR Newswire)
Oct-28-25 04:05PM	CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE (PR Newswire)
Oct-20-25 09:05AM	CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO (PR Newswire)
Oct-13-25 09:05AM	CUMBERLAND PHARMACEUTICALS' VIBATIV ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC. (PR Newswire)
Oct-01-25 09:05AM	CUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICO (PR Newswire)
Sep-29-25 09:05AM	TABUK LAUNCHES VIBATIV FDA-APPROVED ANTIBIOTIC WITH LIFE-SAVING POTENTIAL IN SAUDI ARABIA (PR Newswire)
Aug-06-25 03:25AM	Cumberland Pharmaceuticals Inc (CPIX) Q2 2025 Earnings Call Highlights: Revenue Growth and ... (GuruFocus.com) -15.30%
Aug-05-25 04:19PM	Cumberland: Q2 Earnings Snapshot (Associated Press Finance) -5.49%
04:05PM	Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date (PR Newswire)
Aug-04-25 09:05AM	CUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV 4-VIAL STARTER PAK (PR Newswire) +13.92%
Jul-29-25 04:05PM	CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATE (PR Newswire)
Jun-23-25 09:05AM	Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference (PR Newswire) -9.66%
May-27-25 04:05PM	NEW STUDY FINDS CALDOLOR SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS (PR Newswire) +5.12% +9.36%
May-13-25 04:05PM	CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH (PR Newswire) +5.50% -10.79%
03:20AM	Loading…
May-07-25 03:20AM	Cumberland Pharmaceuticals Inc (CPIX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
May-06-25 04:05PM	Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025 (PR Newswire)
Apr-29-25 04:05PM	CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE (PR Newswire)
Mar-19-25 04:05PM	FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference (PR Newswire)
Mar-05-25 07:49AM	Q4 2024 Cumberland Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +11.90%
02:09AM	Cumberland Pharmaceuticals Inc (CPIX) Q4 2024 Earnings Call Highlights: Revenue Growth and ... (GuruFocus.com)
Mar-04-25 04:50PM	Cumberland: Q4 Earnings Snapshot (Associated Press Finance) +17.70%
04:05PM	Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth (PR Newswire)
Feb-25-25 04:05PM	CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS (PR Newswire) +6.57%
Feb-18-25 07:30AM	VIBATIV RECEIVES MARKETING APPROVAL IN CHINA (PR Newswire) -6.41%
Feb-05-25 05:23AM	Cumberland Pharmaceuticals reports data from trial of ifetroban for DMD (Clinical Trials Arena) +35.11%
Feb-04-25 01:31PM	Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease (Benzinga) +76.53%
07:30AM	Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease (PR Newswire)
Dec-10-24 01:39PM	Cumberland Stock Soars 90% After FDA Approval for Acetadote Dosing Change (GuruFocus.com) +96.77%
12:08PM	Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday? (Benzinga)
Dec-09-24 04:05PM	FDA APPROVES ACETADOTE sNDA (PR Newswire)
Nov-08-24 06:00PM	Cumberland Pharmaceuticals Inc (CPIX) Q3 2024 Earnings Call Highlights: Navigating Challenges ... (GuruFocus.com)
Nov-07-24 05:09PM	Cumberland: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update (PR Newswire)
Nov-06-24 05:21PM	CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (PR Newswire)
Nov-05-24 04:05PM	New Study Compares Caldolor (ibuprofen injection) to ketorolac (PR Newswire)
Oct-31-24 04:05PM	CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS (PR Newswire) -5.88%
Aug-06-24 05:00PM	Cumberland: Q2 Earnings Snapshot (Associated Press Finance) +6.38%
04:05PM	Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024 (PR Newswire)
Jul-30-24 04:05PM	CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2024 FINANCIAL RESULTS (PR Newswire)
May-13-24 08:50AM	Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 06:15AM	Q1 2024 Cumberland Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +5.70%
May-07-24 08:58PM	CPIX Stock Earnings: Cumberland Reported Results for Q1 2024 (InvestorPlace)
05:06PM	Cumberland: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update (PR Newswire)
Apr-30-24 04:05PM	CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS (PR Newswire) -5.60% -11.25%
Apr-02-24 04:05PM	NEW REPORT SUPPORTS USE OF CALDOLOR AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS (PR Newswire)
Mar-07-24 11:52AM	Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q4 2023 Earnings Call Transcript (Insider Monkey) +8.25%
Mar-06-24 06:55AM	Q4 2023 Cumberland Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-05-24 04:26PM	Cumberland: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Cumberland Pharmaceuticals Reports Annual 2023 Financial Results (PR Newswire)
Feb-27-24 04:05PM	CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS (PR Newswire)
Nov-12-23 08:48AM	Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 05:10PM	Cumberland: Q3 Earnings Snapshot (Associated Press Finance) -11.71%
04:05PM	Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results (PR Newswire)
Oct-31-23 04:05PM	CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS (PR Newswire) -10.10%
Oct-10-23 04:05PM	NEW VIBATV PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN PATIENTS 2 TO 17 YEARS OF AGE (PR Newswire) -5.57% +7.69%
Aug-08-23 04:33PM	Cumberland: Q2 Earnings Snapshot (Associated Press Finance) +15.38%
04:05PM	Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023 (PR Newswire)
Aug-01-23 04:05PM	CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS (PR Newswire)
Jun-26-23 09:00AM	NEW PUBLICATION SUPPORTS THE USE OF CALDOLOR® IN NEWBORN PEDIATRIC PATIENTS (PR Newswire)
May-31-23 05:22AM	CPIX: A Solid Stock with an Exciting Catalyst (Zacks Small Cap Research)
May-23-23 09:00AM	CUMBERLAND PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND FOR NEW TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (PR Newswire)
May-15-23 09:00AM	CALDOLOR® NOW FDA APPROVED FOR TREATMENT OF FEVER & PAIN IN INFANTS (PR Newswire) +9.09%
May-09-23 05:29PM	Cumberland: Q1 Earnings Snapshot (AP Finance)
04:05PM	Cumberland Pharmaceuticals Reports First Quarter 2023 Financial Results & Company Update (PR Newswire)
May-02-23 04:05PM	CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2023 FINANCIAL RESULTS (PR Newswire)
Apr-17-23 09:52AM	Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Screens Well But There Might Be A Catch (Simply Wall St.)
Mar-08-23 07:19AM	Q4 2022 Cumberland Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-07-23 04:22PM	CUMBERLAND PHARMACEUTICALS REPORTS 17% REVENUE GROWTH FOR FULL YEAR 2022 (PR Newswire)
Feb-28-23 04:05PM	CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2022 FINANCIAL RESULTS (PR Newswire)
Nov-11-22 06:05AM	Cumberland Pharmaceuticals Third Quarter 2022 Earnings: US$0.028 loss per share (vs US$0.10 loss in 3Q 2021) (Simply Wall St.)
Nov-08-22 04:05PM	Cumberland Pharmaceuticals Reports 41% Revenue Growth (PR Newswire)
Nov-01-22 09:20AM	CUMBERLAND PHARMACEUTICALS MOVES INTO NEW HEADQUARTERS AT BROADWEST (PR Newswire)
Aug-09-22 04:30PM	Edited Transcript of CPIX.OQ earnings conference call or presentation 9-Aug-22 8:30pm GMT (Thomson Reuters StreetEvents) +12.86%
04:05PM	Cumberland Pharmaceuticals Reports 14% Revenue Growth (PR Newswire)
Aug-08-22 09:25AM	CUMBERLAND PHARMACEUTICALS REPORTS 2.4M PATIENT DOSES DELIVERED, NO PRODUCT RECALLS, NO FDA ISSUES IN 2021 (PR Newswire)
Aug-02-22 04:05PM	CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2022 FINANCIAL RESULTS (PR Newswire) -6.06%
Jul-19-22 09:25AM	CUMBERLAND PHARMACEUTICALS APPOINTS MARTIN BROWN JR. TO ITS BOARD OF DIRECTORS (PR Newswire) +10.31%
May-13-22 12:27PM	Estimating The Intrinsic Value Of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) (Simply Wall St.)
May-10-22 04:05PM	Cumberland Pharmaceuticals Reports 6% Revenue Growth (PR Newswire) -14.34%
May-09-22 09:15AM	Cumberland Pharmaceuticals Announces Key Co-Promotion Agreement with Verity Pharmaceuticals to Expand Support for Sancuso® (PR Newswire) +8.71%
May-03-22 04:05PM	CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2022 FINANCIAL RESULTS (PR Newswire)
Mar-31-22 09:20AM	TABUK AND CUMBERLAND PARTNER TO BRING INNOVATIVE ANTIBIOTIC WITH LIFE-SAVING POTENTIAL TO MIDDLE EAST (PR Newswire) +8.46%
Mar-08-22 04:05PM	CUMBERLAND PHARMACEUTICALS REPORTS 2021 FINANCIAL RESULTS & COMPANY UPDATE (PR Newswire) -8.08%

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. Its products include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, Sancuso, Boxaban, Vasculan. Dyscorban, and RediTrex. The company was founded by A. J. Kazimi on January 7, 1999 and is headquartered in Nashville, TN.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Cumberland Pharmaceuticals Inc

Upgrade your Finviz experience